Severe cognitive impairment

Diagnos A.I. retinal screening technology expands into international markets

Retrieved on: 
Thursday, August 5, 2021
Efficiency, Industry, ADK, Optometry, Multimedia, Eye, Toronto Stock Exchange, Severe cognitive impairment, Hospital, Algorithm, Chum, Artificial intelligence, Ai, Retina, Jody Vance, Capillary, Federal Commission for the Protection against Sanitary Risk, Diabetes, EC, Food and Drug Administration, Clinic, FRA, Solution, Anomaly, Population, Technology, Vein, Levon Larents, Cara, Medicine, Stroke, Partnership, Artery, Health Canada, Aneurysm, BCI, Patient safety, Adoption, Atherosclerosis, Blockade IMARC, Patient, Bleeding, AV, Risk, Adult, Iris, Disease, Drug, Medical device, Medical imaging, Telescopic sight, Cryptocurrency, Pharmaceutical industry

CARA's artificial intelligence-based image enhancement algorithms provide sharper, clearer, retinal images that can then be analyzed for anomalies.

Key Points: 
  • CARA's artificial intelligence-based image enhancement algorithms provide sharper, clearer, retinal images that can then be analyzed for anomalies.
  • "IRIS continues to be at the forefront of implementing technology driven solutions for clinical optometry and optical retail," stated said Eric Babin, President of IRIS.
  • "Artificial intelligence will raise our standard when it comes to quality of care and we are eager to collaborate with Diagnos."
  • Diagnos' technology can inform a patient that she is at risk for a heart attack or stroke.

Eyevensys Raises $12M in a Series B Plus Funding Round

Retrieved on: 
Wednesday, August 4, 2021
Health, Genetics, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Wedbush Securities, Korea Investment Partners, Eyevensys, KOREA INVESTMENT PARTNERS, EYEVENSYS

Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today announces it has raised $12M in a Series B Plus funding round.

Key Points: 
  • Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today announces it has raised $12M in a Series B Plus funding round.
  • Korea Investment Partners is leading the Series B Plus financing and existing investors will also join the round.
  • We're thrilled to announce this funding round, which will help us move forward in our mission to develop life-changing solutions for patients with debilitating eye diseases, said Dr. Patricia Zilliox, CEO of Eyevensys.
  • Wedbush PacGrow acted as the exclusive placement agent for the Series B Plus financing.

Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Retinitis Pigmentosa

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Optical, Other Science, Research, Science, Clinical Trials, Clinical medicine, Medicine, Blindness, Channelopathies, Retinitis pigmentosa, Retinitis, Intravitreal administration, Health

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa (RP).

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa (RP).
  • Retinitis pigmentosa is a serious and incurable sight-threatening disease that represents a major unmet need in the field of ophthalmology, stated Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra.
  • "ADX-2191 has now received orphan designations for three distinct clinical indications, highlighting the broad platform potential of ADX-2191 to treat an array of rare retinal disorders.
  • Aldeyra Therapeutics is a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases.

New survey reveals Canadians short sighted when it comes to their eye health

Retrieved on: 
Tuesday, August 3, 2021
Blindness, Glaucoma, Ophthalmology

"The survey revealed that there is room to improve Canadians' education on proper eye care and safety," says Colin Mann, President of the Canadian Ophthalmological Society.

Key Points: 
  • "The survey revealed that there is room to improve Canadians' education on proper eye care and safety," says Colin Mann, President of the Canadian Ophthalmological Society.
  • "While the majority of Canadians are concerned with their eye health overall, some of the misconceptions they have could leave them more vulnerable to one of the four major eye diseases."
  • While these eye diseases are more common amongst those aged 60+, eye care and regular checkups are vital throughout all stages of life.
  • Six in ten Canadians are unaware that many eye diseases, including glaucoma, won't always present symptoms until they are at an advanced stage.

TCN Operator Selected as a 2021 SaaS Awards Finalist for Best SaaS Product for Customer Service/CRM

Retrieved on: 
Tuesday, August 3, 2021
Software, Business models, Cloud applications, Computing, As a service, Software as a service, Software distribution, Software industry, Cloud computing, Saas

ST. GEORGE, Utah, August 3, 2021 /PRNewswire-PRWeb/ -- TCN, Inc. , a global provider of a comprehensive cloud-based call center platform for enterprises, contact centers, BPOs, and collection agencies, today announced its TCN Operator platform has been selected as a finalist in the 2021 SaaS Awards in the Best SaaS Product for Customer Services/CRM category.

Key Points: 
  • ST. GEORGE, Utah, August 3, 2021 /PRNewswire-PRWeb/ -- TCN, Inc. , a global provider of a comprehensive cloud-based call center platform for enterprises, contact centers, BPOs, and collection agencies, today announced its TCN Operator platform has been selected as a finalist in the 2021 SaaS Awards in the Best SaaS Product for Customer Services/CRM category.
  • They represent truly innovative thinkers in the SaaS industry, whether they're freshly-funded disruptors or established names."
  • Launched in May 2021, TCN Operator features a holistic set of easy-to-use, automated agent tools and advanced apps that are designed to boost agent productivity and improve customer experience.
  • Final SaaS Awards winners will be announced on Aug. 31, 2021.

TCN Operator Selected as a 2021 SaaS Awards Finalist for Best SaaS Product for Customer Service/CRM

Retrieved on: 
Tuesday, August 3, 2021
Software, Business models, Cloud applications, Computing, As a service, Software as a service, Software distribution, Software industry, Cloud computing, Saas

ST. GEORGE, Utah, August 3, 2021 /PRNewswire-PRWeb/ -- TCN, Inc. , a global provider of a comprehensive cloud-based call center platform for enterprises, contact centers, BPOs, and collection agencies, today announced its TCN Operator platform has been selected as a finalist in the 2021 SaaS Awards in the Best SaaS Product for Customer Services/CRM category.

Key Points: 
  • ST. GEORGE, Utah, August 3, 2021 /PRNewswire-PRWeb/ -- TCN, Inc. , a global provider of a comprehensive cloud-based call center platform for enterprises, contact centers, BPOs, and collection agencies, today announced its TCN Operator platform has been selected as a finalist in the 2021 SaaS Awards in the Best SaaS Product for Customer Services/CRM category.
  • They represent truly innovative thinkers in the SaaS industry, whether they're freshly-funded disruptors or established names."
  • Launched in May 2021, TCN Operator features a holistic set of easy-to-use, automated agent tools and advanced apps that are designed to boost agent productivity and improve customer experience.
  • Final SaaS Awards winners will be announced on Aug. 31, 2021.

Vision Impact Institute Applauds UN Resolution on Vision

Retrieved on: 
Monday, August 2, 2021
Essilor, EssilorLuxottica, Visual impairment, Optics, Industry economics)

DALLAS, Aug. 2, 2021 /PRNewswire/ -- The Vision Impact Institute applauds the UN General Assembly's adoption of the Vision for Everyone: accelerating action to achieve the Sustainable Development Goals resolution.

Key Points: 
  • DALLAS, Aug. 2, 2021 /PRNewswire/ -- The Vision Impact Institute applauds the UN General Assembly's adoption of the Vision for Everyone: accelerating action to achieve the Sustainable Development Goals resolution.
  • A major step forward for vision correction, this resolution commits the international community to improving vision for 1.1 billion people living with preventable vision loss by 2030.
  • "This resolution is a much-needed step to ensure that good vision is accessible to all," says Kristan Gross , Global Executive Director, Vision Impact Institute.
  • The Vision Impact Institute is a registered 501(c)(3) non-profit organization, which receives support from the Vision for Life Fund from Essilor, the world leader in ophthalmic optics.

Vision Impact Institute Applauds UN Resolution on Vision

Retrieved on: 
Monday, August 2, 2021
Essilor, EssilorLuxottica, Visual impairment, Optics, Industry economics)

DALLAS, Aug. 2, 2021 /PRNewswire/ -- The Vision Impact Institute applauds the UN General Assembly's adoption of the Vision for Everyone: accelerating action to achieve the Sustainable Development Goals resolution. A major step forward for vision correction, this resolution commits the international community to improving vision for 1.1 billion people living with preventable vision loss by 2030.

Key Points: 
  • DALLAS, Aug. 2, 2021 /PRNewswire/ -- The Vision Impact Institute applauds the UN General Assembly's adoption of the Vision for Everyone: accelerating action to achieve the Sustainable Development Goals resolution.
  • A major step forward for vision correction, this resolution commits the international community to improving vision for 1.1 billion people living with preventable vision loss by 2030.
  • "This resolution is a much-needed step to ensure that good vision is accessible to all," says Kristan Gross , Global Executive Director, Vision Impact Institute.
  • The Vision Impact Institute is a registered 501(c)(3) non-profit organization, which receives support from the Vision for Life Fund from Essilor, the world leader in ophthalmic optics.

Born2Global Centre's collaborative initiative with IDB Lab - $600,000 grant awarded to first cross-continental joint venture partnerships

Retrieved on: 
Monday, August 2, 2021
Business incubators, Entrepreneurship, Private equity, Startup company

The startup pairs that are deemed to have the most imminent impact in their respective industries were approved by the IDB Lab to receive an equity-free grant fund of $120,000 in accelerating the initial stages of their collaborative partnership.

Key Points: 
  • The startup pairs that are deemed to have the most imminent impact in their respective industries were approved by the IDB Lab to receive an equity-free grant fund of $120,000 in accelerating the initial stages of their collaborative partnership.
  • The successful approval of the five startup pairs has been crucial proof that despite pandemic-related restrictions, intercontinental partnerships between startups is possible, opening doors for new possibilities in collaborative efforts.
  • JongKap Kim, the Chief Executive Director of Born2Global Centre, said, "The joint venture-type partnerships between startups created through the Korea-LAC Deep Tech Exchange program with IDB Lab was a challenging attempt to promote collaborative R&DB amid the pandemic."
  • Born2Global has expanded and transformed startups to be engaged, equipped and connected with the global market.